IRIS
GRAGNANO, Felice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.621
AS - Asia 3.649
NA - Nord America 2.548
SA - Sud America 689
AF - Africa 66
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.582
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 6.708
US - Stati Uniti d'America 2.479
SG - Singapore 1.373
CN - Cina 877
IE - Irlanda 771
HK - Hong Kong 634
BR - Brasile 585
IT - Italia 333
VN - Vietnam 247
GB - Regno Unito 203
KR - Corea 201
DE - Germania 184
IN - India 131
FR - Francia 90
UA - Ucraina 55
GR - Grecia 53
AR - Argentina 47
AT - Austria 45
FI - Finlandia 43
SE - Svezia 38
MX - Messico 30
JP - Giappone 29
CA - Canada 28
BD - Bangladesh 27
BE - Belgio 22
TR - Turchia 22
ID - Indonesia 20
CO - Colombia 18
IQ - Iraq 18
NL - Olanda 17
EG - Egitto 14
ES - Italia 13
MA - Marocco 13
PK - Pakistan 13
ZA - Sudafrica 13
KE - Kenya 12
EC - Ecuador 11
PL - Polonia 10
UZ - Uzbekistan 9
LT - Lituania 7
VE - Venezuela 7
CL - Cile 6
SA - Arabia Saudita 6
HN - Honduras 5
JO - Giordania 5
PY - Paraguay 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
CZ - Repubblica Ceca 4
IL - Israele 4
NO - Norvegia 4
PE - Perù 4
RS - Serbia 4
TW - Taiwan 4
UY - Uruguay 4
EU - Europa 3
IR - Iran 3
KZ - Kazakistan 3
MD - Moldavia 3
NP - Nepal 3
TH - Thailandia 3
AM - Armenia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
MY - Malesia 2
AL - Albania 1
AN - Antille olandesi 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
PW - Palau 1
RO - Romania 1
Totale 15.578
Salva come PNG Salva come JPEG
Città #
Moscow 2.449
Dublin 757
Santa Clara 656
Hong Kong 631
Singapore 506
Chandler 359
Hefei 246
Seoul 197
Beijing 125
The Dalles 102
Jacksonville 100
New York 96
Princeton 94
Roxbury 94
Bengaluru 90
Ho Chi Minh City 89
Ashburn 87
Dallas 67
Naples 60
Hanoi 51
São Paulo 51
Cambridge 49
Nuremberg 49
Medford 48
Bremen 44
Falkenstein 35
Des Moines 32
Boardman 29
Los Angeles 28
Ann Arbor 26
Caserta 26
Wilmington 24
Brussels 22
Rio de Janeiro 19
Aversa 18
Lappeenranta 18
Da Nang 15
Helsinki 15
Hyderabad 15
Nanjing 15
Belo Horizonte 14
Vienna 14
Munich 13
Brooklyn 11
Dhaka 11
Guangzhou 11
Houston 11
Boston 10
Brasília 10
Campinas 10
Curitiba 10
Ercolano 10
Nairobi 10
Napoli 10
Porto Alegre 10
Rome 10
Amsterdam 9
Haiphong 9
Jinan 9
Mexico City 9
Milan 9
Montreal 9
Salvador 9
Tashkent 9
Bogotá 8
Columbus 8
Johannesburg 8
London 8
Norwalk 8
San Francisco 8
Sivas 8
Frankfurt am Main 7
Hangzhou 7
Stockholm 7
Turku 7
Baghdad 6
Cairo 6
Changsha 6
Ninh Bình 6
Phoenix 6
San Giovanni In Fiore 6
Thái Bình 6
Toronto 6
Woodbridge 6
Zhengzhou 6
Afragola 5
Amman 5
Bauru 5
Casablanca 5
Guarulhos 5
Hải Dương 5
Juiz de Fora 5
Las Vegas 5
Lấp Vò 5
Nova Iguaçu 5
Santo André 5
Shanghai 5
Shenzhen 5
Tunis 5
Turin 5
Totale 7.900
Salva come PNG Salva come JPEG
Nome #
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 193
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 156
MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients 152
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 145
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 144
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 142
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 142
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 141
Natural history of left ventricular hypertrophy in infants of diabetic mothers 138
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 137
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team 133
[Device therapy in chronic heart failure: a case of hypertrophic cardiomyopathy treated with cardiac contractility modulation therapy] 132
[The COMPASS study] 132
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 130
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 130
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 127
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial 125
A call for action in bleeding prevention 124
Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy 123
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 118
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 116
Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future perspectives 116
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 115
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 115
[Evaluation and percutaneous treatment of severely calcified coronary lesions] 115
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation 114
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 113
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 113
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 113
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 111
Anticoagulation After Primary PCI: The Land of Promises and Uncertainty 107
Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience 106
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 106
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 104
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up 104
[Gut microbiota and the cardiovascular system: current evidence and future perspectives] 104
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 103
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 103
[Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease] 102
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 102
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 100
Early-onset MINOCA: Prognostic implications and considerations for practice 100
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 100
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 98
Are we ready for a gender-specific approach in interventional cardiology? 98
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 97
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 97
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 97
Von Willebrand Factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target 97
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 96
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 96
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 96
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy? 95
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 95
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 95
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 94
Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions 93
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest 93
null 93
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 92
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies 92
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 92
Simulation Models of Therapy Intensification in Lipid-Lowering Medicine: Fact or Fantasy? 91
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018) 91
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 91
Inflammation in patients undergoing transcatheter aortic valve implantation: a therapeutic target for the future? 90
von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications 90
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy 90
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry 88
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 88
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition 88
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 87
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 87
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials 87
CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach? 87
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 86
A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience 83
Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines 83
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 82
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 82
Letter by Calabro and Gragnano Regarding Article, "Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials" 82
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 82
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 82
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 82
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy? 81
A pragmatic approach for thrombotic prevention after acute coronary syndromes 81
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions 81
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 81
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 81
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 81
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 80
How has COVID-19 impacted the care of patients with acute coronary syndromes? 80
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry 80
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 80
Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias? 80
OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold 79
SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection 79
Prognostic implications of ischemia with nonobstructive coronary arteries (INOCA): Understanding risks for improving treatment 79
Long-term antiplatelet monotherapy after PCI: searching for the smart choice 78
Severely calcified coronary artery lesions: focus on interventional management 78
Totale 10.230
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.940
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.940
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021196 0 0 0 0 0 2 61 11 19 13 62 28
2021/2022778 10 1 8 28 194 11 12 121 21 93 59 220
2022/20231.332 129 73 32 93 121 72 4 69 672 8 26 33
2023/2024734 44 21 22 37 191 108 54 6 6 33 54 158
2024/20252.890 7 28 8 77 452 383 357 237 403 463 280 195
2025/20269.692 458 679 657 587 954 6.357 0 0 0 0 0 0
Totale 16.080